# Estimating epidemiologic dynamics from single crosssectional viral load distributions

James A. Hay<sup>\*1,2,3†</sup>, Lee Kennedy-Shaffer<sup>\*1,2,4†</sup>, Sanjat Kanjilal<sup>5,6</sup>, Marc Lipsitch<sup>1,2,3</sup>, Michael J. Mina<sup>1,2,3†</sup>

\* These authors contributed equally.

<sup>1</sup> Center for Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, Boston, MA

<sup>2</sup> Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA

<sup>3</sup> Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA

<sup>4</sup> Department of Mathematics and Statistics, Vassar College, Poughkeepsie, NY

<sup>5</sup> Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA

<sup>6</sup> Department of Infectious Diseases, Brigham and Women's Hospital, Boston, MA

<sup>†</sup> Correspondence should be addressed to: <u>jhay@hsph.harvad.edu</u> (J.A.H.), <u>lkennedyshaffer@vassar.edu</u> (L.K.S.), <u>mmina@hsph.harvard.edu</u> (M.J.M.)

### Funding

This work is supported by U.S. National Institutes of Health Director's Early Independence Award DP5-OD028145 (MJM, JAH), the Morris-Singer Fund (LKS and ML), U.S. Centers for Disease Control and Prevention Award U01IP001121 (LKS and ML), and U.S. National Institute of General Medical Sciences award U54GM088558 (ML, JAH, LKS).

#### Data availability

All code is available at <u>https://github.com/jameshay218/ct\_dynamics\_preprint</u>. The Ct values from Massachusetts will be made available in a later version of this manuscript.

1

### 1 Abstract

2 Virologic testing for SARS-CoV-2 has been central to the COVID-19 pandemic response, but 3 interpreting changes in incidence and fraction of positive tests towards understanding the 4 epidemic trajectory is confounded by changes in testing practices. Here, we show that the 5 distribution of viral loads, in the form of Cycle thresholds (Ct), from positive surveillance samples 6 at a single point in time can provide accurate estimation of an epidemic's trajectory, subverting 7 the need for repeated case count measurements which are frequently obscured by changes in 8 testing capacity. We identify a relationship between the population-level cross-sectional 9 distribution of Ct values and the growth rate of the epidemic, demonstrating how the skewness 10 and median of detectable Ct values change purely as a mathematical epidemiologic rule without 11 any change in individual level viral load kinetics or testing. Although at the individual level 12 measurement variation can complicate interpretation of Ct values for clinical use, we show that 13 population-level properties reflect underlying epidemic dynamics. In support of these theoretical 14 findings, we observe a strong relationship between the time-varying effective reproductive 15 number, R(t), and the distribution of Cts among positive surveillance specimens, including median 16 and skewness, measured in Massachusetts over time. We use the observed relationships to 17 derive a novel method that allows accurate inference of epidemic growth rate using the distribution 18 of Ct values observed at a single cross-section in time, which, unlike estimates based on case 19 counts, is less susceptible to biases from delays in test results and from changing testing 20 practices. Our findings suggest that instead of discarding individual Ct values from positive 21 specimens, incorporation of viral loads into public health data streams offers a new approach for 22 real-time resource allocation and assessment of outbreak mitigation strategies, even where 23 repeat incidence data is not available. Ct values or similar viral load data should be regularly 24 reported to public health officials by testing centers and incorporated into monitoring programs.

### 25 Introduction

26 Tracking trends in the incidence of infection during an epidemic are vital for deciding on 27 appropriate public health response measures (1-3). This information can help decision-makers 28 understand the need for and efficacy of non-pharmaceutical interventions, to plan the deployment 29 of public health resources, and the use of scarce hospital beds and personal protective 30 equipment. In the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, 31 estimating the outbreak trajectory and key epidemiological parameters such as the time-varying 32 effective reproductive number, R(t), has generally been done by using daily observed case 33 counts, percent of tests positive, or death counts, ideally confirmed by reverse-transcription 34 quantitative polymerase chain reaction (RT-qPCR) testing. Because of the nonspecific symptoms 35 and variable incubation periods of COVID-19 (4, 5), the limited and time-varying availability of 36 testing in many parts of the world, including in the United States, and the delay between infections 37 and reported tests or confirmed deaths (6), these approaches are limited in their ability to reliably 38 and promptly detect underlying changes in infection counts (7). In particular, whether changes in 39 case counts at different times have stemmed from changes in testing or reflect epidemic growth 40 or decay have been major topics of debate with important economic, health and political 41 ramifications.

42 Virologic testing is an important method for determining the infection status of an individual and 43 the prevalence of infection in a community. RT-qPCR testing is currently the primary approach 44 for virus detection (8, 9). While these tests have quantitative results in the form of cycle threshold 45 (Ct) values, which are inversely correlated with  $log_{10}$  viral loads, they are often reported only as 46 binary results (10, 11). Previous work for other infectious diseases has focused on identifying 47 correlations between Ct values and clinical severity and transmissibility (12-14). In addition, Ct 48 values or viral loads may be useful in clinical determinations about the need for isolation and 49 quarantine for SARS-CoV-2 (11, 15), in determining the phase of an individual's infection (16, 17) 50 and predicting disease severity (16, 18).

51 Using viral loads for clinical and epidemiological purposes requires an understanding of the viral 52 load kinetics over the course of infection. For SARS-CoV-2, this has not been fully characterized 53 due to difficulties in quickly identifying and repeatedly testing asymptomatic infections. However, 54 many salient features of the viral load trajectory have been identified using rhesus macaque 55 models and longitudinal human studies with repeated sampling after symptom onset (*19–25*).

56 From these properties, assessments of infectiousness over the course of infection (*5, 26*) and 57 population-level viral load distributions by time since infection can be reconstructed (*27*).

58 While individual viral load kinetic trajectories may potentially be used to diagnose the clinical 59 course of infection and determine requirements of test sensitivities (27), albeit with caveats from 60 sampling variability and different testing platforms, population-level viral loads can be used for 61 epidemiological assessments of an outbreak. Sample surveys with virologic tests provide cross-62 sectional estimation of the prevalence of infection, and repeated surveys can provide information 63 on the trends in prevalence and incidence over time (28). Population-level signals in 64 measurements obtained under the same sampling protocol and using the same instrument will 65 therefore reflect underlying epidemiological trends. However, a consistently observed but 66 currently unexplained phenomenon is that, as the epidemic declines, the distribution of observed 67 Ct values above the limit of detection appears to systematically decline (15, 16).

68 Previous work has used serologic data to infer unobserved individual-level infection events and 69 population-level parameters of infectious disease spread. In particular, antibody dynamics have 70 been used in tools to identify the infecting strain for multi-strain pathogens (29, 30) and to identify 71 the time since infection for an individual (31, 32). At the population level, repeated sampling of 72 antibody levels has been used to identify seasonal forcing mechanisms for recurrent epidemics 73 (33), estimate an average incidence rate (34-37), and identify the force of infection at various 74 time points (32, 38). Although virologic data may exhibit more heterogeneity than serological data, 75 they similarly provide single point-in-time observations of underlying within-host infection kinetics. 76 Here, we use virologic data, which can be obtained sooner after infection than antibody titers, to 77 provide real-time monitoring of epidemic dynamics, and demonstrate an approach using a single 78 cross-sectional survey.

79 In this paper, we show that the changing population distribution of Ct values obtained from positive 80 SARS-CoV-2 samples can be used to infer epidemic dynamics. Early in the epidemic, infection 81 numbers are growing rapidly and the average infection is recent; as the epidemic wanes, 82 however, average time since exposure increases as the rate of new infections decreases-83 analogous to the average age being lower in a growing vs. declining population of organisms (39). 84 Importantly, within infected hosts, Ct values change over time: the viral population undergoes 85 rapid exponential growth after inoculation, succeeded by slower exponential decline as the 86 infection is cleared and low levels of viral RNA persist. Surveillance sampling of infected 87 individuals during epidemic growth is therefore more likely to measure individuals who were

recently infected and therefore in the acute phase of their infection. Conversely, sampling infected 88 89 individuals during epidemic decline is more likely to capture individuals in the convalescent phase, 90 typically sampling lower quantities of viral RNA. We first demonstrate that rate of transmission is 91 highly correlated with the distribution of detectable Ct values in infected individuals over time using 92 both simulated and real data from Massachusetts. We then formalize this intuition into a novel 93 and robust method able to use viral load measurements (i.e., RT-qPCR Ct values or other forms 94 of virus quantitation) from single cross-sectional virologic test surveys to determine an 95 instantaneous outbreak trajectory, without need for repeated measures.

### 96 **Results**

### 97 Relationship between observed Ct values and epidemic dynamics


98 To first demonstrate how the distribution of observed Ct values changes over the course of an 99 outbreak, we simulate viral load trajectories from infections arising under a deterministic 100 susceptible-exposed-infectious-recovered (SEIR) model (Fig. 1A). At each day of the outbreak, 101 Ct values are observed from a random sample of the population using the population-level Ct 102 distribution model described in Materials and Methods and shown in Fig. S1. Assumed parameter 103 values for the distribution of Ct values for a given time since infection are the point estimates in 104 **Table S1**, capturing individual-level time courses of viral kinetics post infection and the substantial 105 variation in observations resulting from individual variation and sampling differences. By drawing 106 simulated samples for testing from across the population at specific time points, these simulations 107 recreate realistic cross-sectional distributions of detectable viral loads across the course of an 108 epidemic.

109 Throughout the course of the outbreak, shown in **Fig. 1**, there is a strong relationship between 110 growth rate of new infections at each timepoint, the cross-sectional distribution of time since 111 infection of RT-gPCR-detectable infections at that time point, and distribution of detectable viral 112 loads in the simulated SEIR population at that time point. To infer epidemic growth rate, we would 113 ideally observe the distribution of time since infection of infected individuals, because it is directly 114 related to the average growth rate when those individuals were infected (Fig. 1A-C). However, 115 because infections are often unobserved events, we rely on an observable quantity, such as viral 116 load, as a proxy for the time since infection (Fig. 1D-G). Throughout, we assume that there is a 117 single infection time for each individual and ignore re-infection, as it appears to be a negligible 118 portion of infections in the epidemic so far (40).

119 Since the viral load is related to time since infection for each individual (Fig. 1D), and the average 120 time since infection varies over the outbreak (Fig. 1C), the distributional properties of the 121 measured viral loads (i.e., median and skewness) vary with the growth rate of new cases (Fig. 122 1H, Fig. S2). Across individuals, this relationship holds, even after accounting for significant 123 individual level variation in peak viral loads and growth/clearance kinetics and errors in quantifying 124 viral load. This relationship holds for any observation model (i.e., using a different RT-gPCR 125 instrument or in a different lab); if the distribution of observations is an estimable function of the 126 distribution of times since infection (which it is), then the expected median and skewness of 127 observations at a given point in time are predictable from the growth rate.

### 128 Demonstration using simulated data


129 We used our simulation framework to investigate how properties of the Ct distribution relate to 130 the effective reproductive number, R(t), if observed in a population similar to Massachusetts, USA. 131 Here, R(t) is used essentially as a reflection of the growth, or decay, of the epidemic in time. We 132 find that both the median Ct (which would vary with the individual assay) as well as the skewness 133 of the Ct distribution (which would be largely test- and lab-agnostic) show a strong correlation with 134 R(t) (Fig. 2); as R(t) declines, the median Ct of sampled individuals increases and, notably, the 135 distribution becomes more negatively skewed. An important caveat for this comparison is that 136 R(t) is the effective reproductive number on that day, whereas Ct values are observed from 137 infections generated across many days in the past.



138

139 Figure 1. (A) Simulated per capita incidence, daily growth rate, and average growth rate over the preceding 140 35 days of detectable infections. Binocular symbols represent observation times used in subsequent plots. 141 (B) Relationship between growth rate as it varies over the epidemic and the median time since infection. 142 (C) Distribution of times since infection for observed, detectable infections at 50, 75, 100, 125, and 150 143 days after the epidemic start (histograms) and daily median (thick green line) and central 50% percentiles 144 for time since infection. (D) Modeled mean viral kinetics on each day post infection. Labels show mean Ct 145 value corresponding to the median time since infection at different points along the epidemic curve. (E) 146 Simulated RT-gPCR cycle threshold (Ct) value trajectories of 500 individuals randomly sampled from the 147 epidemic. Swab symbols represent sampling times. (F) Modeled viral kinetics showing median Ct value 148 (purple line) and 95% quantiles on simulated observations. (G) Distribution of observed, detectable Ct 149 values at each of the five test days (histograms) and median and central 50% percentiles (thick and thin 150 lines, respectively) on Ct values observed over time. (H) between growth rate and the skew of the

151 observable Ct distribution. All results are based on an SEIR model in a population of 1,000,000 with  $R_0$  = 152 2.5, average latent period of 6.41 days, and average infectious period of 8.79 days, and Ct values were 153 simulated based on inferred post-infection viral kinetics. In **E**, for visual simplicity, each individual's Ct 154 values are assumed to follow the same post-infection trajectory with only a shift in the mean; this 155 assumption is not used elsewhere in this paper.




156

**Figure 2. (A)** Simulated incidence of new infections (red) and corresponding effective reproductive number over time, R(t) (green). **(B)** Weekly distribution of positive (detectable) Ct values. The blue line shows the smoothed median, the dotplot shows a subset of the observed, binned Ct values, and the violin plot shows densities. **(C&D)** Relationship between the skewness and median of the observed Ct distribution and the mean R(t) per week. Blue line and shaded region shows fitted smoothing spline +/- 1 standard error. Only weeks with more than 10 detectable Ct values are shown. **(E)** Plotted together, the median and skewness of the observed Ct distribution display a strong correlation with R(t) (color of point) per week.

#### 164 Observation of trends in Ct values from a major tertiary care hospital in Massachusetts

165 To investigate if our predicted relationship between the distribution of Ct values and R(t) is borne 166 out in reality, we used fully anonymized Ct values measured from nearly all hospital admissions 167 into Brigham & Women's Hospital in Boston, MA, between April 3 and August 31, 2020, and 168 aligned them with estimates for R(t) based on case counts in Massachusetts. Tests taken prior to 169 April 3 were restricted to symptomatic patients only, while those after April 15 represented 170 universal testing of all hospital admission, regardless of symptomatology. The median and 171 skewness of the Ct distribution both dropped during this period, strikingly similar to our predictions 172 for the peak and subsequent decline of an epidemic. Although the trend was the same, properties 173 of the Ct distribution exhibited higher variation across weeks, likely resulting from changes in 174 transmission intensity (e.g., due to the implementation of and adherence to interventions), small 175 sample sizes in some weeks, and potential sampling bias. In particular, it is important to note that 176 sampling was initially biased in early April towards symptomatic individuals, resulting in more 177 individuals being sampled near the peak of their viral loads (i.e., symptom onset), and therefore 178 skewing the Ct distribution towards lower values. Indeed, we were able to recreate this positive 179 skew by simulating observed Ct values with early biased sampling towards symptomatic 180 individuals (Fig. S3). Nevertheless, the relationship held. Importantly for monitoring potential, the 181 relationship demonstrated slight reductions in median Ct (increases in median viral load) and 182 slightly reduced negative skew as cases, and thus estimated R(t), began to increase again in the 183 state in July (Fig. 3).






185 Figure 3. (A) Estimates of the effective reproductive number, R(t) (black line and green area), based on 186 the daily incidence of new cases in Massachusetts (grey bars). We used the EpiNow2 package (see 187 Materials and Methods), which uses a Bayesian approach to first back-calculate incidence by date of 188 infection (red line and region) and subsequently infer R(t). Shaded regions show 95% credible intervals and 189 solid lines show posterior means. (B) Weekly distribution of positive (detectable) Ct values from Brigham & 190 Women's Hospital in Boston, MA. The blue line shows the smoothed median, the dotplot shows the 191 observed, binned Ct values, and the violin plot shows densities. (C&D) Relationship between the skewness 192 and median of the observed Ct distribution per day against the posterior mean daily R(t). Blue line and 193 shaded region shows fitted smoothing spline +/- 1 standard error. Only days with more than 10 detectable 194 Ct values are shown. (E) As in Fig. 2, the median and skewness of the observed Ct distribution can be 195 combined to demonstrate a strong correlation with R(t) (color of point) per day.

#### 196 Epidemic growth rates can be inferred based on cross-sectional viral load data

197 Next, we derive a method to formally infer the epidemic growth rate given a single cross-section 198 of observed, detectable Ct values. If the population-level distribution of Ct values on each day 199 post infection is known, then the distribution of observed Ct values from a largely random sample 200 of infected individuals will reflect their times since infection, which in turn reflects the growth rate 201 when those individuals were infected. The likelihood of the observed viral loads can then be 202 written as a function of the growth rate (Materials and Methods), allowing estimation of the 203 average growth rate at any time point in the outbreak. In many cases, especially for a novel 204 infection such as SARS-CoV-2, the population-level dynamics of viral loads and the resulting 205 distribution of Ct values following infection may not be known with certainty. However, available 206 data and qualitative understanding can be sufficient to define Bayesian priors for estimating key 207 viral kinetics parameters. We therefore developed a Bayesian framework to incorporate uncertain 208 prior distributions on the population-level Ct distribution as well as on the growth rate.

209 Using the same simulated population as in **Fig. 2**, we fit the model to cross-sectional samples at 210 5 day intervals using the Bayesian priors in **Table S1**. These analyses demonstrate how a 211 single cross-sectional sample of individuals may be used to estimate properties of the outbreak. 212 Fig. 4A shows the posterior growth rate estimates alongside the true growth rate at each time 213 point. The credible interval widths reflect the number of detectable Ct values included in each 214 cross-section, and also uncertainty in the viral kinetics and Ct distribution parameters. Larger 215 sample sizes than we drew here and stronger accurate priors would help constrain these 216 estimates. However, with large uncertainties incorporated in this particular version of the 217 framework, the method was still able to discern if the growth rate was positive or negative, even 218 if the point estimates were imprecise (Fig. 4B). Fig. 4C and 4D demonstrates how the model is 219 fitted to the observed Ct distribution and the corresponding time-since-infection distribution for 220 individuals observed on a particular day.



222 Figure 4. (A) Epidemic growth models independently fit to cross sections at 5-day intervals. The black line 223 shows infection incidence. The orange line shows the average growth rate over the 35 days preceding each 224 day. The pointrange plot shows the posterior median and 95% credible intervals (CIs) of the average growth 225 rate estimated on that day. Points are colored by the number of detectable Ct values used for fitting. (B) 226 Posterior growth rate estimates against true 35-day average growth rates. Dashed line shows the 1:1 line. 227 Points and ranges show posterior medians and 95% CIs respectively. (C) Model-predicted Ct distributions 228 (line and blue shaded region) fitted to the observed Ct distribution (histogram) during epidemic growth, peak 229 and decline phases. Black line and blue region show posterior median and 95% CIs. (D) Posterior estimates for the relative time since infection distribution during epidemic growth, peak and decline phases. Light 230 231 shaded region shows 95% CIs, dark shaded region shows central 95% CIs, and solid line shows posterior 232 mean. Note that the x-axis is reversed, such that the left hand side shows older infections and the right 233 hand side shows more recent infections.

221

### 234 **Discussion**

235 The usefulness of Ct values for public health decision making is currently the subject of much 236 discussion and debate. One unexplained observation which has been consistently observed in 237 many locations is that the distribution of observed Ct values has decreased over the course of 238 the current SARS-CoV-2 pandemic, which has led to questions over whether the virus has lost 239 some amount of fitness (15, 16, 18). Our results demonstrate instead that this is expected as a 240 purely epidemiologic phenomenon, without any change in individual-level viral dynamics or testing 241 practices. We find that properties of the population-level Ct distribution strongly correlate with 242 estimates for the effective reproductive number in Massachusetts in line with our theoretical 243 predictions. The method described here uses this phenomenon to estimate a community's 244 position in the epidemic curve, as defined by the growth rate, based on a single cross-sectional 245 survey of virologic test data. We propose a simple method to monitor the skewness and median 246 of the Ct value distribution to estimate changes in the epidemic trajectory. Despite the challenges 247 of sampling variability, individual-level differences in viral kinetics, and limitations in comparing 248 results from different laboratories or instruments, our results demonstrate that Ct values, with all 249 of their quantitative variability for an individual, can be highly informative of population-level 250 dynamics. This information is lost when measurements are reduced to binary classifications.

251 These results are sensitive to the true distribution of observed viral loads each day after infection. 252 Different swab types, sample types, or instruments may alter the variability in the Ct distribution 253 (41.42), leading to different relationships between the specific Ct distribution and the epidemic 254 trajectory. Setting-specific calibrations, for example based on a reference range of Ct values, will 255 be useful to ensure accuracy. Here, we generated a viral kinetics model based on observed 256 properties of measured viral loads (proportion detectable over time following symptom onset, 257 distribution of Ct values from true specimens), and used these results to inform priors on key 258 parameters when estimating growth rates. The growth rate estimates can therefore be improved 259 by choosing more precise, accurate priors relevant to the observations used during model fitting. 260 Results could also be improved if the symptom status of the sampled individuals is known, 261 allowing the inclusion of viral kinetics parameters specific to symptomatic individuals (16, 43). The 262 same may be true if demographic features such as age are associated with viral load levels. 263 although there is limited evidence to suggest this so far (16, 18, 24, 44). The distribution could 264 also be adjusted to account for any individuals treated with antivirals, such as remdesivir, that 265 may reduce viral loads (45). A similar approach may also be possible using serologic surveys, as

an extension of work that has related time since infection to antibody titers for other infectiousdiseases (*32, 38*).

268 Our results demonstrate that this method can be used to estimate epidemic growth rates based 269 on data collected at a single time point, and independent of assumptions about the intensity of 270 testing. Comparisons of simulated Ct values and observed Ct values with growth rates and R(t)271 estimates validate this general approach. Results should be interpreted with caution in cases 272 where the observed Ct values are not from a population census or a largely random sample. 273 When testing is based primarily on the presence of symptoms or follow-up of contacts of infected 274 individuals, people may be more likely to be sampled at specific times since infection and thus 275 the distribution of observed Cts would not be representative of the population as a whole. This 276 method may be most useful in settings where representative surveillance samples can be 277 obtained independent of COVID-19 symptoms—and importantly in cities or municipalities that 278 wish to evaluate and monitor, in real-time, the role of various epidemic mitigation interventions, 279 for example by conducting even a single random virologic testing effort as part of surveillance.

280 This method has a number of limitations. While the Bayesian framework incorporates the 281 uncertainty in viral load distributions into inference on the growth rate, parametric assumptions 282 and reasonably strong priors on these distributions aid in identifiability. If these parametric 283 assumptions are violated, inference may not be reliable. This method may also overstate 284 uncertainty in the viral load distributions if results from different machines or protocols are used 285 to inform the prior. A more precise understanding of the viral load kinetics, and modeling those 286 kinetics in a way that accounts for the epidemiologic and technical setting of the measurements, 287 will help improve this approach and determine whether Ct distribution parameters from different 288 settings are comparable. Because of this, quantitative measures from RT-qPCR should be 289 reported regularly for SARS-CoV-2 cases and early assessment of pathogen load kinetics should 290 be a priority for future emerging infections. The use of a control procedure in the measurements, 291 like using the ratio of detected viral RNA to detected human RNA, could also improve the reliability 292 and comparability of Ct measures.

Future research will evaluate how to incorporate these results into an overall inferential framework for real-time monitoring of epidemic trajectories. In particular, we are currently adapting the framework to combine multiple cross-sectional datasets, include the proportion of negative viral tests in the likelihood, and to use more flexible parametric assumptions for epidemic growth. By using Ct values to determine the growth rate of incident cases and using virologic positivity rates

to assess prevalence of infection, as well as potentially incorporating measured covariates and
 symptom status, a richer picture of the path and likely future of an outbreak can be realized from
 one or more virologic surveys.

301 The Ct value is a measurement with magnitude, which provides information on underlying viral 302 dynamics. Although there are challenges to relying on single Ct values for individual-level decision 303 making, the aggregation of many such measurements from a population contains substantial 304 information. These results demonstrate how population-level distributions of Ct values can 305 provide information on important epidemiologic questions of interest, even from a single cross-306 sectional survey. Better epidemic planning and more targeted epidemiological measures can then 307 be implemented based on this survey, or use of Ct values can be combined with repeated 308 sampling to maximize the use of available evidence.

### 309 Materials and Methods

### 310 Model for Population-Level Ct Distribution

We fit a model for the distribution of viral loads at a given day after infection, a. Denote this density

by  $p_a(x)$ , where x is the viral load. We denote by  $\phi_a$  the probability that an individual will have a

313 detectable viral load *a* days after infection.

314 This model is fit based on several key features of the viral load kinetics that have been determined 315 for SARS-CoV-2 infection. In symptomatic cases, detectable viral loads occur prior to the onset 316 of symptoms and generally decline after symptom onset (19, 46, 47). Since infectiousness 317 appears to peak before symptom onset, viral load likely does as well (26). Challenge studies in 318 rhesus macaques indicate that viral load peaks around 2 days after infection (22, 23). Combined 319 with evidence of an incubation period in humans of around 5 days (5), these observations suggest 320 rapid exponential rise to a peak viral load during the incubation period and a high viral load upon 321 symptom onset of approximately 6–9 log<sub>10</sub> copies RNA per mL (19, 25). However, most existing 322 viral load time series begin after symptom onset, and it is therefore difficult to corroborate 323 assumptions for the pre-symptomatic period. Waning of viral loads occurs following symptom 324 onsets, with a majority of patients undetectable around 24 days after onset (19, 20, 24, 25). At 325 any point in the infection, there is a considerable amount of person-to-person variation in viral 326 loads (19, 25), including a possible difference by symptom status (20, 48). This may also reflect 327 protocols used to test the samples and the site and method of sample collection (25).

We develop a parametric model for the population-level distribution of Ct values. The measured Ct value *a* days after infection follows a Gumbel distribution with a mean that depends on *a* and a fixed standard deviation *SD*. The mean log-viral load at day *a* follows a two-hinge function that is at the true zero value of  $VL_{zero}$  for  $a \le t_{shift}$ , rises linearly to a peak log-viral load of  $VL_{peak}$  at  $a = t_{peak}$ , wanes linearly to a log-viral load of  $VL_{switch}$  at  $a = t_{switch}$ , and then wanes at a slower linear rate until it reaches the limit of detection (LOD), a log-viral load of  $VL_{LOD}$  at  $a = t_{LOD}$ . That is, the mean log-viral load is given by:

$$VL_{mean}(a) = VL_{zero} + I_{a>t_{shift}} \frac{VL_{peak} - VL_{zero}}{t_{peak} - t_{shift}} (a - t_{shift}) + I_{a>t_{peak}} \frac{VL_{switch} - VL_{peak}}{t_{switch} - t_{peak}} (a - t_{peak})$$

$$(a - t_{switch}) + I_{a>t_{switch}} \frac{VL_{LOD} - VL_{switch}}{t_{LOD} - t_{switch}} (a - t_{switch}).$$

337 The log-viral load is converted to a Ct value by:  $Ct_{mean}(a) = Ct_{LOD} - log_2(10) (VL_{mean}(a) - log_2(10)) (VL_{mean}(a))$ 338  $VL_{LOD}$ ) where the limit of detection on the Ct scale is  $Ct_{LOD} = 40$  and on the viral load scale is 339  $VL_{LOD} = 3$ . The Ct value at a days after infection, Ct(a), is then distributed according to  $p_a(Ct)$ , a 340 Gumbel distribution with mean  $Ct_{mean}(a)$  and variance  $SD^2$ . This model captures the shape of 341 the observed mean viral load over time and the features described above. However, it 342 overestimates the proportion of infections that will be detectable three weeks or more after 343 infection. To account for this, each day after  $t_{switch}$ , we add an additional probability,  $p_{addl}$ , that an 344 individual will clear the virus and become undetectable for that day forward, in addition to the 345 probability that the Ct value rises above the limit of detection. So the probability of being 346 detectable on day  $a \leq t_{switch}$  is  $\phi_a = P[Ct(a) \leq Ct_{LOD}]$  and the probability of being detectable on day  $a > t_{switch}$  is  $\phi_a = P[Ct(a) \le Ct_{LOD}](1 - p_{addl})^{a - t_{switch}}$ . 347

348 We used a least-squares optimization framework to obtain parameter point estimates that gave 349 rise to viral kinetics with the following constraints: the proportion of individuals that are detectable 350 on each day post symptom onset declines in line with existing data (49), and the lower 99<sup>th</sup> 351 percentile of possible Ct values is in line with the lowest observed Ct value in our Brigham & 352 Women's Hospital dataset. We used these point estimates to derive informative priors on key 353 model parameters, as described in Table S1. The resulting distribution of Ct values and 354 detectable proportions at each day a after infection are shown in **Fig. S1**. These parameters are 355 used as fixed parameters for the schematic (Fig. 1).

### 356 Likelihood for Parametric Model of Outbreak Trajectory

357 Given a known population-level Ct distribution for each day after infection and a known 358 detectable probability,  $p_a(x)$  and  $\phi_a$ , respectively, we can determine the likelihood of the 359 probability of infection a days prior to the test day,  $\pi_a$ , for all a with a positive probability of 360 detectable viral load, given the observed detectable viral loads  $x_1, \ldots, x_n$ . Let  $\{A_{min}, \ldots, A_{max}\}$ 361 denote the days with a positive probability of detectable viral load, so that an individual with a detectable viral load must have been infected between  $A_{max}$  and  $A_{min}$  days prior to testing. We 362 363 further assume that each individual's viral load is independent of the viral load of other 364 individuals in the sample, conditional on the probability of infection for each day.

365 
$$P(X_i = x_i | \pi_{A_{min}}, \dots, \pi_{A_{max}}) = \sum_{a=A_{min}}^{A_{max}} \frac{p_a(x_i) \pi_a}{\sum_{c=A_{min}}^{A_{max}} \phi_c \pi_c}$$

366 Thus, the likelihood and log-likelihood, respectively, are given by:

367 
$$L(\pi_{A_{min}}, \dots, \pi_{A_{max}} | X_1 = x_1, \dots, X_n = x_n) = \prod_{i=1}^n \sum_{a=A_{min}}^{A_{max}} \frac{p_a(x_i) \pi_a}{\sum_{c=A_{min}}^{A_{max}} \phi_c \pi_c}$$
, and

$$368 \quad l(\pi_{A_{min}}, \dots, \pi_{A_{max}} | X_1 = x_1, \dots, X_n = x_n) = \sum_{i=1}^n \left\{ log \left[ \sum_{a=A_{min}}^{A_{max}} p_a(x_i) \pi_a \right] - 369 \quad log \left[ \sum_{c=A_{min}}^{A_{max}} \phi_c \pi_c \right] \right\}.$$

370

- 371 Assume that the outbreak, over the days prior to testing, is experiencing exponential growth or
- decline of the daily probability of infection. Then for each day  $a \in \{A_{min}, \dots, A_{max}\}, \pi_a =$

373  $\frac{e^{-\beta a}}{\sum_{d=A_{min}}^{A_{max}} e^{-\beta d}}$ . Note that  $\beta > 0$  implies a growing outbreak,  $\beta < 0$  a waning outbreak, and  $\beta = 0$ 

a flat outbreak with a constant probability of infection across the days prior to testing. Then the

375 likelihood and log-likelihood for  $\beta$  given the observed viral loads are:

376 
$$P(X_1 = x_1, \dots, X_n = x_n | \beta) = \prod_{i=1}^n \sum_{a=A_{min}}^{A_{max}} \frac{p_a(x_i) e^{-\beta a}}{\sum_{c=A_{min}}^{A_{max}} \phi_c e^{-\beta c}}$$

377 
$$l(\beta|X_1 = x_1, \dots, X_n = x_n) = \sum_{i=1}^n \left\{ log \left[ \sum_{a=A_{min}}^{A_{max}} p_a(x_i) e^{-\beta a} \right] - log \left[ \sum_{c=A_{min}}^{A_{max}} \phi_c e^{-\beta c} \right] \right\}$$

378 More flexible parametric models can be used, including assuming piecewise exponential growth 379 or that the probability of infection on each day follows some other function. In these cases, the 380 parametric model for  $\pi_a$  is simply used in place of  $e^{-\beta a}$  in this likelihood and log-likelihood.

Additionally, nonparametric estimation can be performed by maximizing the likelihood in terms of  $\pi_a$  directly for  $a \in \{A_{min}, \dots, A_{max}\}$ . This approach, however, will likely give very high variance unless there is a large sample size and the viral distribution has a small variance

384 compared to the trend in the mean over time.

#### 385 Bayesian Framework for Estimation and Inference

- 386 To incorporate uncertainty in the distribution of viral loads on each day after infection, we
- 387 construct a Bayesian framework for estimation and inference. A prior distribution is specified for
- 388  $\beta$  (or the set of parameters used in the likelihood) as well as for the viral load distributions,  $p_a(x)$ .
- 389 The prior for the viral load distributions can be specified in many ways, but we here

parameterize these distributions by a mean and standard deviation for each day a and assume

- a normal distribution with those parameters, so the prior is specified on the mean and standard
- deviation. This prior can be based on existing studies of viral load kinetics after infection and
- 393 can also take into account specific properties of the sample collection procedure, PCR
- 394 protocols, and machine used to analyze the samples, if known. Estimation and inference can
- then proceed on the posterior distribution.

396 The prior distributions used here are listed in **Table S1**. The prior distribution for  $\beta$  is taken to be

- 397 normal with mean 0 and standard deviation 0.1. Note that  $\beta = 0.4$  corresponds to a doubling
- time of 1.73 days, so value of  $\beta$  above 0.4 or below -0.4 would be highly unusual for SARS-CoV-2.

400 To assess the outbreak trajectory, interest lies in the marginal posterior distribution of  $\beta$ . A

401 larger positive value of  $\beta$  indicates a faster-growing outbreak and a more negative value of

402  $\beta$  indicates a faster-waning outbreak. The posterior distribution of the  $p_a(x)$  parameters are

403 nuisance parameters for this goal, but may provide useful information for the prior distributions

404 of  $p_a(x)$  in future studies in similar settings.

### 405 Simulated Data

For **Fig. 1**, outbreaks are simulated according to a deterministic SEIR model with a population of 1,000,000 people,  $R_0$ =2.5, average latent period of 6.41 days, and average infectiousness period of 8.79 days. The latent and infectiousness periods are based on the best fit SEIR models for the observed prevalences in Massachusetts nursing home data (not shown) and align fairly well with the viral load kinetics implied by the Ct distribution model and with parameters reported elsewhere (5, 50).

412 For **Figs. 2** and **4**, outbreaks are simulated according to a stochastic SEIR model with a population 413 of 6,900,000 people, an initial seed of 100 infected individuals,  $R_0=2$ , average latent period of 414 6.41 days, and average infectiousness period of 8.79 days as above. We used the odin R package 415 for simulation (https://cran.r-project.org/web/packages/odin/index.html). To simulate cross-416 sectional sampling, we assumed that 20% of the population was randomly sampled once during the outbreak, which led to approximately 4,000 individuals being sampled and tested per day. 417 418 Each infected individual is then assigned an observed Ct value on the day of sampling using the 419 viral kinetics model described in Model for Population-Level Ct Distribution, with added 420 observation error drawn from a Gumbel distribution with a standard deviation of 6. Fig. S3 is

421 generated in the same way, but with additional samples taken from symptomatic individuals. We 422 assumed that 35% of infections became symptomatic, and that symptomatic individuals had a 423 10% probability of being detected. Detected, symptomatic individuals were observed with some 424 delay post symptom onset drawn from a discretized gamma distribution with shape and rate 425 parameters of 5 and 2 respectively (mean and standard deviation of 2.5 and 1 days respectively).

### 426 Brigham & Women's Hospital data, Boston, Massachusetts

427 Data comes from nasopharyngeal specimens processed on a Hologic Panther Fusion SARS-428 CoV-2 assay for patients at the Brigham & Women's Hospital in Boston, MA. Testing during the 429 first two weeks in April 2020 were restricted to patients with symptoms consistent with COVID-19 430 and who needed hospital admission. Following April 15, testing criteria were expanded to include 431 all hospital admissions regardless of symptoms and asymptomatic ER patients who were not 432 admitted. The results were from individuals entering the hospital for non-COVID procedures and 433 thus represent less biased surveillance specimens. Daily data is aggregated by week. Daily 434 confirmed case counts for Massachusetts were obtained from the NYT github page 435 (https://github.com/nytimes/covid-19-data) (51).

#### 436 Estimating the effective reproductive number, *R*(*t*)

437 We EpiNow2 R R(t)used the package for all estimates 438 (https://github.com/epiforecasts/EpiNow2). The package estimates the time-varying reproduction 439 number using the MCMC package Stan (https://cran.r-440 project.org/web/packages/rstan/index.html), incorporating best practices in R(t) estimation as 441 described by Gostic et al. (52–54). The package takes a time series of confirmed case counts as 442 input, and returns posterior distribution estimates on the daily effective reproductive number. 443 *EpiNow2* simultaneously infers R(t) and infection incidence using a method based on the Cori 444 method. We assumed that the confirmation delay distribution was log normally distributed with a 445 mean of 3 (on the linear scale) and standard deviation of 0.5 (on the log scale) days. We assumed 446 that the generation interval and incubation period were uncertain, using the default values 447 provided by the *EpiNow2* package. The mean and standard deviation of the generation interval 448 were assumed to be 3.64 and 3.07 days respectively, with standard deviations for Bayesian priors 449 on these parameters of 0.711 and 0.770 respectively. The incubation period was assumed to be 450 log-normally distributed, with mean and standard deviation (both on the log scale) of 1.621 and 451 0.418 respectively, with standard deviations for Bayesian priors on these parameters of 0.064

- 452 and 0.0691 respectively. We used a smoothing window of 7 days and ran 4 chains each for 4000
- 453 iterations with 1000 iterations of warm up.

### References

- 1. H. V. Fineberg, M. E. Wilson. Epidemic science in real time. Science 324, 987 (2009).
- 2. Y. Hsieh, D. N. Fisman, J. Wu. On epidemic modeling in real time: An application to the 2009 Novel A (H1N1) influenza outbreak in Canada. *BMC Res. Notes* **3**, 283 (2010).
- J. Lourenço, R. Paton, M. Ghafari, M. Kraemer, C. Thompson, P. Simmonds, P. Klenerman, S. Gupta. Fundamental principles of epidemic spread highlight the immediate need for large-scale serological surveys to assess the stage of the SARS-CoV-2 epidemic. https://www.medrxiv.org/content/10.1101/2020.03.24.20042291v1 (2020).
- T. K. Tsang, P. Wu, Y. Lin, E. H. Y. Lau, G. M. Leung, B. J. Cowling. Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling study. *Lancet Public Health* 5, e289–296 (2020).
- S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng, H. R. Meredith, A. S. Azman, N. G. Reich, J. Lessler. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. *Ann. Int. Med.* **172**, 577–582 (2020).
- T. Jombart, K. van Zandvoort, T. W. Russell, C. I. Jarvis, A. Gimma, S. Abbott, S. Clifford, S. Funk, H. Gibbs, Y. Liu, C. A. B. Pearson, N. I. Bosse, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group, R. M. Eggo, A. J. Kucharski, W. J. Edmunds. Inferring the number of COVID-19 cases from recently reported deaths. *Wellcome Open Res.* 5 (2020).
- 7. M. Lipsitch, D. L. Swerdlow, L. Finelli. Defining the epidemiology of COVID-19—studies needed. *NEJM* **382**, 1194–1196 (2020).
- 8. A. Tahamtan, A. Ardebili. Real-time RT-PCR in COVID-19 detection: issues affecting the results. *Expert Rev. Mol. Diagn.* **20**, 453–454 (2020).
- 9. C. P. West, V. M. Montori, P. Sampathkumar. COVID-19 testing: the threat of falsenegative results. *Mayo Clin. Proc.* **95**, 1127–1129 (2020).
- 10. J. L. Vaerman, P. Saussoy, I. Ingargiola. Evaluation of real-time PCR data. *J. Biol. Regul. Homeost. Agents* **18**, 212–214 (2004).
- 11. M. R. Tom, M. J. Mina. To interpret the SARS-CoV-2 test, consider the cycle threshold value. *Clin. Inf. Dis.* <u>10.1093/cid/ciaa619</u> (2020).
- 12. J. A. Fuller, M. K. Njenga, G. Bigogo, B. Aura, M. O. Ope, L. Nderitu, L. Wakhule, D. D. Erdman, R. F. Breiman, D. R. Feikin. Association of the C<sub>T</sub> values of real-time PCR of viral upper respiratory tract infection with clinical severity, Kenya. *J. Med. Virol.* 85, 924–932 (2013).
- S. Bolotin, S. L. Deeks, A. Marchand-Austin, H. Rilkoff, V. Dang, R. Walton, A. Hashim, D. Farrell, N. S. Crowcroft. Correlation of Real Time PCR Cycle Threshold Cut-Off with *Bordetella pertussis* Clinical Severity. *PLoS One* **10**, e0133209 (2015).

- T. K. Tsang, B. J. Cowling, V. J. Fang, K. H. Chan, D. K. M. Ip, G. M. Leung, J. S. M. Peiris, S. Cauchemez. Influenza A virus shedding and infectivity in households. *J. Inf. Dis.* 212, 1420–1428 (2015).
- M. Moraz, D. Jacot, M. Papadimitriou-Olivgeris, L. Senn, G. Greub, K. Jaton, O. Opota. Clinical importance of reporting SARS-CoV-2 viral loads across the different stages of the COVID-19 pandemic. <u>https://www.medrxiv.org/content/10.1101/2020.07.10.20149773v1</u> (2020).
- 16. D. Jacot, G. Greub, K. Jaton, O. Opota. Viral load of SARS-CoV-2 across patients and compared to other respiratory viruses. https://www.medrxiv.org/content/10.1101/2020.07.15.20154518v1 (2020).
- 17. Y. Chen, L. Li. SARS-CoV-2: virus dynamics and host response. *Lancet Inf. Dis.* **20**, 515–516 (2020).
- T. C. Jones, B. Mühlemann, T. Veith, G. Biele, M. Zuchowski, J. Hoffmann, A. Stein, A. Edelmann, V. M. Corman, C. Drosten. An analysis of SARS-CoV-2 viral load by patient age. <u>https://www.medrxiv.org/content/10.1101/2020.06.08.20125484v1</u> (2020).
- K. K. W. To, O. T. Y. Tsang, W. S. Leung, A. R. Tam, T. C. Wu, D. C. Lung, C. C. Y. Yip, J. P. Cai, J. M. C. Chan, T. S. H. Chik, D. P. L. Lau, C. Y. C. Choi, L. L. Chen, W. M. Chan, K. H. Chan, J. D. Ip, A. C. K. Ng, R. W. S. Poon, C. T. Luo, Vi. C. C. Cheng, J. F. W. Chan, I. F. N. Hung, Z. Chen, H. Chen, K. Y. Yuen. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Inf. Dis.* 20, 565–574 (2020).
- 20. Q. Z. Long, X. J. Tang, Q. L. Shi, Q. Li, H. J. Deng, J. Yuan, J. L. Hu, W. Xu, Y. Zhang, F. J. Lv, K. Su, F. Zhang, J. Gong, B. Wu, X. M. Liu, J. J. Li, J. F. Qiu, J. Chen, A. L. Huang. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nature Med*. <u>10.1038/s41591-020-0965-6</u> (2020).
- M. Cevik, M. Tate, O. Lloyd, A. E. Maraolo, J Schafers, A. Ho. SARS-CoV-2 viral load dynamics, duration of viral shedding and infectiousness – a living systematic review and meta-analysis. <u>https://www.medrxiv.org/content/10.1101/2020.07.25.20162107v1</u> (2020)
- A. Chandrashekar, J. Liu, A. J. Martinot, K. McMahan, N. B. Mercado, L. Peter, L. H. Tostanoski, J. Yu, Z. Maliga, M. Nekorchuk, K. Busman-Sahay, M. Terry, L. M. Wrijil, S. Ducat, D. R. Martinez, C. Atyeo, S. Fischinger, J. S. Burke, M. D. Slein, L. Pessaint, A. Van Ry, J. Greenhouse, T. Taylor, K. Blade, A. Cook, B. Finneyfrock, R. Brown, E. Teow, J. Velasco, R. Zahn, F. Wegmann, P. Abbink, E. A. Bondzie, G. Dagotto, M. S. Gebre, X. He, C. Jacob-Dolan, N. Kordana, Z. Li, M. A. Lifton, S. H. Mahrokhian, L. F. Maxfield, R. Nityanandam, J. P. Nkolola, A. G. Schmidt, A. D. Miller, R. S. Baric, G. Alter, P. K. Sorger, J. D. Estes, H. Andersen, M. G. Lewis, D. H. Barouch. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science* <u>10.1126/science.abc4776</u> (2020).
- J. Yu, L. H. Tostanoski, L. Peter, N. B. Mercado, K. McMahan, S. H. Mahrokhian, J. P. Nkolola, J. Liu, Z. Li, A. Chandrashekar, D. R. Martinez, C. Loos, C. Atyeo, S. Fischinger, J. S. Burke, M. D. Slein, Y. Chen, A. Zuiani, F. J. N. Lelis, M. Travers, S. Habibi, L. Pessaint, A. Van Ry, K. Blade, R. Brown, A. Cook, B. Finneyfrock, A. Dodson, E. Teow, J. Velasco, R. Zahn, F. Wegmann, E. A. Bondzie, G. Dagotto, M. S. Gebre, X. He, C. Jacob-Dolan, M. Kirilova, N. Kordana, Z. Lin, L. F. Maxfield, F. Nampanya, R. Nityanandam, J. D. Ventura, H. Wan, Y. Cai, B. Chen, A. G. Schmidt, D. R. Wesemann,

R. S. Baric, G. Alter, H. Andersen, M. G. Lewis, D. H. Barouch. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science* <u>10.1126/science.abc6284</u> (2020).

- 24. A. T. Xiao, Y. X. Tong, S. Zhang. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. *Clin. Inf. Dis.* <u>10.1093/cid/ciaa460</u> (2020).
- 25. R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A. Müller, D. Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brünink, J. Schneider, R. Ehmann, K. Zwirglmaier, C. Drosten, C. Wendtner. Virological assessment of hospitalized patients with COVID-19. *Nature* **581**, 465–469 (2020).
- 26. X. He, E. H. Y. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. Guan, X. Tan, X. Mo, Y. Chen, B. Liao, W. Chen, F. Hu, Q. Zhang, M. Zhong, Y. Wu, L. Zhao, F. Zhang, B. J. Cowling, F. Li, G. M. Leung. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Med.* 26, 672–675 (2020).
- 27. D. B. Larremore, B. Wilder, E. Lester, S. Shehata, J. M. Burke, J. A. Hay, M. Tambe, M. J. Mina, R. Parker. Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance. https://www.medrxiv.org/content/10.1101/2020.06.22.20136309v2 (2020).
- S. Riley, K. E. C. Ainslie, O. Eales, B. Jeffrey, C. E. Walters, C. J. Atchison, P. J. Diggle, D. Ashby, C. A. Donnelly, G. Cooke, W. Barclay, H. Ward, G. Taylor, A. Darzi, P. Elliott. Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT study. <u>https://www.medrxiv.org/content/10.1101/2020.07.10.20150524v1</u> (2020).
- H. Salje, D. A. T. Cummings, I. Rodriguez-Barraquer, L. C. Katzelnick, J. Lessler, C. Klungthong, B. Thaisomboonsuk, A. Nisalak, A. Weg, D. Ellison, L. Macareo, I. K. Yoon, R. Jarman, S. Thomas, A. L. Rothman, T. Endy, S. Cauchemez. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. *Nature* 557, 719–723 (2018).
- 30. J. A. Hay, A. Minter, K. E. C. Ainslie, J. Lessler, B. Yang, D. A. T. Cummings, A. J. Kucharski, S. Riley. An open source tool to infer epidemiological and immunological dynamics from serological data: serosolver. *PLoS Comput. Biol.* **16**, e1007840 (2020).
- B. Borremans, N. Hens, P. Beutels, H. Leirs, J. Reijniers. Estimating time of infection using prior serological and individual information can greatly improve incidence estimation of human and wildlife infections. *PLoS Comput. Biol.* 12, e1004882 (2016).
- 32. K. M. Pepin, S. L. Kay, B. D. Golas, S. S. Shriner, A. T. Gilbert, R. S. Miller, A. L. Graham, S. Riley, P. C. Cross, M. D. Samuel, M. B. Hooten, J. A. Hoeting, J. O. Lloyd-Smith, C. T. Webb, M. G. Buhnerkempe. Inferring infection hazard in wildlife populations by linking data across individual and population scales. *Ecol. Lett.* **20**, 275–292 (2017).
- X. Zhao, Y. Ning, M. I. C. Chen, A. R. Cook. Individual and population trajectories of influenza antibody titers over multiple seasons in a tropical country. *Am. J. Epidemiol.* 187, 135–143 (2018).
- 34. D. De Angelis, W. R. Gilks, N. E. Day. Bayesian projection of the acquired immune deficiency syndrome epidemic. *J. R. Stat. Soc. Ser. C Appl. Stat.* **47**, 449–498 (1998).

- 35. H. E. de Melker, F. G. A. Versteegh, J. F. P. Schellekens, P. F. M. Teunis, M. Kretzschmar. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. *J. Infect.* **53**, 106–113 (2006).
- 36. J. Simonsen, K. Mølbak, G. Falkenhorst, K. A. Krogfelt, A. Linneberg, P. F. M. Teunis. Estimation of incidences of infectious diseases based on antibody measurements. *Stat. Med.* 28, 1882–1895 (2009).
- 37. P. F. M. Teunis, J. C. H. van Eijkeren, C. W. Ang, Y. T. H. P. van Duynhoven, J. B. Simonsen, M. A. Strid, W. van Pelt. Biomarker dynamics: estimating infection rates from serological data. *Stat. Med.* **31**, 2240–2248 (2012).
- D. A. Helb, K. K. A. Tetteh, P. L. Felgner, J. Skinner, A. Hubbard, E. Arinaitwe, H. Mayanja-Kizza, I. Ssewanyana, M. R. Kamya, J. G. Beeson, J. Tappero, D. L. Smith, P. D. Crompton, P. J. Rosenthal, G. Dorsey, C. J. Drakeley, B. Greenhouse. Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities. *Proc. Natl. Acad. Sci. U.S.A.* **112**, E4438–E4447 (2015).
- 39. J. Wallinga, M. Lipsitch. How generation intervals shape the relationship between growth rates and reproductive numbers. *Proc. R. Soc. B* **274**, 599–604 (2007).
- M. Gousseff, P. Penot, L. Gallay, D. Batisse, N. Benech, K. Bouiller, R. Collarino, A. Conrad, D. Slama, C. Joseph, A. Lemaignen, F.-X. Lescure, B. Levy, M. Mahevas, B. Pozzetto, N. Vignier, B. Wyplosz, D. Salmon, F. Goehringer, E. Botelho-Nevers. Clinical recurrences of COVID-19 symptoms after recovery: viral lapse, reinfection or inflammatory rebound? *J. Infect.* <u>10.1016/j.jinf.2020.06.073</u> (2020).
- R. Niehus, E. van Kleef, A. Turlej-Rogacka, C. Lammens, Y. Carmeli, H. Goossens, E. Tacconelli, B. Carevic, L. Preotescu, S. Malhotra-Kumar, B. S. Cooper. Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance. *eLife* **9**, e49206 (2020).
- 42. D. Rhoads, D. R. Peaper, R. C. She, F. S. Nolte, C. M. Wojewoda, N. W. Anderson, B. S. Pritt. College of American Pathologists (CAP) Microbiology Committee perspective: caution must be used in interpreting the cycle threshold (Ct) value. *Clin. Infect. Dis.* <u>10.1093/cid/ciaa1199</u> (2020).
- Z. Zhang, T. Xiao, Y. Wang, J. Yuan, H. Ye, L. Wei, H. Wang, X. Liao, S. Qian, Z. Wang, L. Liu. Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers. <u>https://www.medrxiv.org/content/10.1101/2020.04.28.20083139v1</u> (2020).
- 44. L. Held. A discussion and reanalysis of the results reported in Jones et al. (2020). https://osf.io/bkuar/ (2020).
- 45. W.-C. Ko, J.-M. Rolain, N.-Y. Lee, P.-L. Chen, C.-T. Huang, P.-I. Lee, P.-R. Hsueh. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. *Int. J. Antimicrob. Agents* **55**, 105933 (2020).
- M. Arons, K. M. Hatfield, S. C. Reddy, A. Kimball, A. James, J. R. Jacobs, J. Taylor, K. Spicer, A. C. Bardossy, L. P. Oakley, S. Tanwar, J. W. Dyal, J. Harney, Z. Chisty, J. M. Bell, M. Methner, P. Paul, C. M. Carlson, H. P. McLaughlin, N. Thornburg, S. Tong, A. Tamin, Y. Tao, A. Uehara, J. Harcourt, S. Clark, C. Brostrom-Smith, L. C. Page, M. Kay, J. Lewis, P. Montgomery, N. D. Stone, T. A. Clark, M. A. Honein, J. S. Duchin, J. A.

Jernigan. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. *NEJM* **382**, 2081–2090 (2020).


- 47. J. Y. Kim, J. H. Ko, Y. Kim, Y. J. Kim, J. M. Kim, Y. S. Chung, H. M. Kim, M. G. Han, S. Y. Kim, B. S. Chin. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. *J. Korean Med. Sci.* **35**, e86 (2020).
- 48. Y. Liu, L. M. Yan, L. Wan, T. X. Xiang, A. Le, J. M. Liu, M. Peiris, L. L. M. Poon, W. Zhang. Viral dynamics in mild and severe cases of COVID-19. *Lancet Inf. Dis.* 20, 656–657 (2020).
- B. Borremans, A. Gamble, K. C. Prager, S. K. Helman, A. M. McClain, C. Cox, V. Savage, J. O. Lloyd-Smith. Quantifying antibody kinetics and RNA shedding during early-phase SARS-CoV-2 infection. https://www.medrxiv.org/content/10.1101/2020.05.15.20103275v1 (2020).
- S. T. Ali, L. Wang, E. H. Y. Lau, X.-K. Xu, Z. Du, Y. Wu, G. M. Leung, B. J. Cowling. Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions. *Science* <u>10.1126/science.abc9004</u> (2020).
- 51. The New York Times. Covid in the U.S.: Latest Map and Case Count. *New York Times* 2020. Accessed at <u>https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html</u> on September 8, 2020.
- 52. S. Abbott, J. Hellewell, R. N. Thompson, K. Sherratt, H. P. Gibbs, N. I. Bosse, J. D. Munday, S. Meakin, E. L. Doughty, J. Y. Chun, Y. W. D. Chan, F. Finger, P. Campbell, A. Endo, C. A. B. Pearson, A. Gimma, T. Russell, CMMID COVID modelling group, S. Flasche, A. J. Kucharski, R. M. Eggo, S. Funk. Estimating the time-varying reproduction number of SARS-CoV-2 using national and subnational case counts. *Wellcome Open Res.* [awaiting peer review] **5**, 112 (2020).
- 53. B. Carpenter, A. Gelman, M. D. Hoffman, D. Lee, B. Goodrich, M. Betancourt, M. A. Brubaker, J. Guo, P. Li, A. Riddell. Stan: a probabilistic programming language. *J. Stat. Softw.* **76**, v076i01 (2017).
- 54. K. M. Gostic, L. McGough, E. B. Baskerville, S. Abbott, K. Joshi, C. Tedijanto, R. Kahn, R. Niehaus, J. Hay, P. M. De Salazar, J. Hellewell, S. Meakin, J. Munday, N. I. Bosse, K. Sherrat, R. N. Thompson, L. F. White, J. S. Huisman, J. Scire, S. Bonhoeffer, T. Stadler, J. Wallinga, S. Funk, M. Lipsitch, S. Cobey. Practical considerations for measuring the effective reproductive number, Rt. <a href="https://www.medrxiv.org/content/10.1101/2020.06.18.20134858v3">https://www.medrxiv.org/content/10.1101/2020.06.18.20134858v3</a> (2020).

## **Supplementary Figures and Tables**


Table S1. Parameters in the viral load and cycle threshold (Ct) value distribution. Point estimates shown
are used in the simulations for Figs. 1, 4, S1, and S2. Bayesian priors are used in Fig. 4.

Parameter	Description	Prior distribution	Point estimate (mean)	Standard deviation
β	Exponential growth rate	Normal	0	0.10
t <sub>shift</sub>	Time (in days) from infection to start of growth of viral load	Fixed	2.00	NA
t <sub>peak</sub>	Time (in days) from infection to peak viral load	Fixed	4.00	NA
<b>t</b> switch	Time (in days) from infection to start of reduced waning viral load rate and additional probability of becoming undetectable	Normal	16.0	1.00
<b>t</b> LOD	Time (in days) from <i>t</i> <sub>switch</sub> until the mean viral load is equal to the limit of detection ( <i>VL</i> <sub>LOD</sub> )	Normal	30.0	1.50
VLzero	Mean viral load (in $log_{10}$ copies RNA per mL) for $a \le t_{shift}$	Fixed	-3.00	NA
VL <sub>peak</sub>	Mean peak viral load (in $log_{10}$ copies RNA per mL) at $a = t_{peak}$	Normal	9.00	1.00
VLswitch	Mean viral load (in $log_{10}$ copies RNA per mL) at $a = t_{switch}$	Normal	3.70	0.125
SD	Standard deviation (for Gumbel	Normal	6.00	0.50


	distribution) of cycle threshold (Ct) values around mean at any day <i>a</i>			
Paddl	Probability of becoming permanently undetectable each day for $a > t_{switch}$	Beta	0.12	0.05
CtLOD	Limit of detection for Ct values	Fixed	40.0	NA
VLLOD	Limit of detection for viral loads (in log <sub>10</sub> copies RNA per mL)	Fixed	3.00	NA



**Figure S1**. **(A)** Mean cycle threshold (Ct) value, mean viral load, and distribution of Ct values for detectable infections by time since infection. **(B)** Proportion of infections that are detectable by time since infection for the population-level Ct distribution. The proportion of infections that are detectable is indicated by the color of the violin plot and the proportion detectable line. The dashed line indicates the limit of detection (Ct value of 40 or viral load of 3).



**Figure S2**. Relationship between time since infection and detectable cycle threshold (Ct) distribution and growth rate. The median and skew of the time since infection distribution are directly related to growth rate. Although the time since infection distribution (blue lines indicate median, top, and skew, bottom, of time-since-infection) is not observed directly, Ct values can be used as a proxy observation model. The solid green line shows the observation model assumed for Fig. 1, whereas the faint green line shows how a relationship would still exist for an alternative observation model, the two differing, for example, by different tests in different labs. The test days shown in Fig. 1 are indicated by points. All results are based on an SEIR model in a population of 1,000,000 with  $R_0 = 2.5$ , average latent period of 6.41 days, and average infectious period of 8.79 days, and Ct values are distributed according to the population-level Ct value distribution.



**Figure S3.** Weekly distribution of positive (detectable) Ct values as in **Fig. 2**, but up to day 125 sampled individuals are a combination of randomly sampled cross-sections and individuals sampled in the days immediately after symptom onset, assuming that 35% of infections become symptomatic. The blue line shows the smoothed median from only cross-sectionally sampled individuals, whereas the purple line shows the smoothed median from combined cross-sectional and symptomatic sampled individuals. The violin plot shows densities of all sampled individuals. For these simulations, all symptomatic individuals had a 10% probability of being detected up to day 125. For detected individuals, we added a delay between symptom onset and sampling time drawn from a discretized gamma distribution with a mean of 2.5 days and standard deviation of 1 day.